300 results found.

Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent S Clinical Trial using soy isoflavones; laboratory biomarker analysis; survey administration

National Cancer Institute (NCI) - Recruiting 19 years to 79 years.
- A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma.
soy isoflavones; laboratory biomarker analysis; survey administration

Adult Primary Hepatocellular Carcinoma, Localized Unresectable Ad Clinical Trial using sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.
sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

Renal Cell Carcinoma Clinical Trial using everolimus and bevacizumab

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC).
everolimus and bevacizumab

Carcinoma, Hepatocellular Clinical Trial using TACE (transarterial chemoembolization); Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib.
TACE (transarterial chemoembolization); Sorafenib (Nexavar, BAY43-9006)

Colorectal Cancer Metastatic Clinical Trial using TheraSphere

BTG International Inc. - Recruiting 18 years or older.
- A Phase III Clinical Trial Evaluating TheraSpherer in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy.
TheraSphere

Carcinoma, Renal Cell Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma.
Sorafenib (Nexavar, BAY43-9006)

Metastatic Colorectal Cancer, Metastatic Gastric Cancer, Metastat Clinical Trial using CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers.
CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

Newly Diagnosed Carcinoma of Breast, or Genetic Predisposition to Clinical Trial

Northwestern University - Recruiting 18 years or older.
- 4R (Right Information and Right Care to the Right Patient at the Right Time) for Guideline Indicated BRCA Genetic Assessment of Breast Center Patients.

Nasopharyngeal Carcinoma Clinical Trial using Drug: Gemcitabine and cisplatin; Cisplatin

First People's Hospital of Foshan - Recruiting 18 years to 60 years.
- Randomized Phase ? Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
Drug: Gemcitabine and cisplatin; Cisplatin

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Women at Increased Risk for Developing Breast Carcinoma Clinical Trial using Mammography (CESM) and MRI

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older.
- Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer.
Mammography (CESM) and MRI

Stage IA Endometrial Carcinoma, Stage IB Endometrial Carcinoma, S Clinical Trial using lymph node mapping; sentinel lymph node biopsy; isosulfan blue; indocyanine green solution; therapeutic conventional surgery; lymphadenectomy

Case Comprehensive Cancer Center - Recruiting N/A or older.
- Sentinel Lymph Node Mapping for Endometrial Cancer.
lymph node mapping; sentinel lymph node biopsy; isosulfan blue; indocyanine green solution; therapeutic conventional surgery; lymphadenectomy

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Head and Neck Neoplasms Clinical Trial using methotrexate; afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy.
methotrexate; afatinib

Head and Neck Neoplasms Clinical Trial using Placebo; Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma.
Placebo; Afatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib; loperamide

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM).
afatinib; loperamide

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Carcinoma, Hepatocellular Clinical Trial using Nintedanib high dose; Nintedanib low dose; Nintedanib medium dose

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma..
Nintedanib high dose; Nintedanib low dose; Nintedanib medium dose

Hepatocellular Carcinoma Clinical Trial using Cabozantinib (XL184); Placebo

Exelixis - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib.
Cabozantinib (XL184); Placebo

Carcinoma, Non-Small-Cell Lung Clinical Trial using Dose escalation followed by treatment with MTD

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations.
Dose escalation followed by treatment with MTD

Colorectal Carcinoma Clinical Trial using BBI608; Placebo; Best Supportive Care

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma.
BBI608; Placebo; Best Supportive Care

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Liver Cancer Clinical Trial using yttrium Y 90 glass microspheres; Cisplatin; Mitomycin; Doxorubicin

Northwestern University - Recruiting 18 years or older.
- An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial).
yttrium Y 90 glass microspheres; Cisplatin; Mitomycin; Doxorubicin

Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adeno Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

Carcinoma, or Lymphoma Clinical Trial using rh IL-15

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers.
rh IL-15

Breast Cancer, Lobular Carcinoma, or Invasive Breast Cancer Clinical Trial using Tissue specimen

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ.
Tissue specimen

BRCA1 Mutation, or BRCA2 Mutation Clinical Trial using Radical fimbriectomy; Histopathology SEE-FIM

Centre Oscar Lambret - Recruiting 35 years or older.
- Radical Fimbriectomy for Young BRCA Mutation Carriers at Risk of Pelvic Serous Carcinoma.
Radical fimbriectomy; Histopathology SEE-FIM

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using tivantinib; cetuximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of ARQ 197 (Tivantinib) /Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer.
tivantinib; cetuximab; laboratory biomarker analysis

Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, or Clinical Trial using cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Cabozantinib With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using fulvestrant; anastrozole

Alliance for Clinical Trials in Oncology - Recruiting 18 years or older.
- Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
fulvestrant; anastrozole

Adenocarcinoma of Head of Pancreas, Cholangio Carcinoma, Duodenal Clinical Trial using Open surgery; Laparoscopic surgery

GEM Hospital & Research Center - Recruiting 30 years to 70 years.
- A Prospective Randomized Parallel Group Trial : Laparoscopic Versus Open Pancreatoduodenectomy in Terms of Pathological Radicality & Severity Short Term of Complications According to Expanded Accordion Severity Grading System.
Open surgery; Laparoscopic surgery

Carcinoma, Hepatocellular Clinical Trial using Everolimus; Tacrolimus; Myfortic; CellCept

Baylor Research Institute - Recruiting 18 years or older.
- A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria.
Everolimus; Tacrolimus; Myfortic; CellCept

Renal Cell Carcinoma Clinical Trial using Cabozantinib (XL184); Everolimus (Afinitor)

Exelixis - Recruiting 18 years or older.
- A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy.
Cabozantinib (XL184); Everolimus (Afinitor)

Head and Neck Cancer Clinical Trial using MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Basal Cell Carcinoma Clinical Trial

Genentech - Recruiting 18 years or older.
- A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients.

Solid Cancers Clinical Trial using Vismodegib

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function.
Vismodegib

Carcinoma, Squamous Cell, Mouth Neoplasms, Oropharyngeal Neoplasm Clinical Trial

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 30 years to 80 years.
- Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers.

Non-small Cell Lung Carcinoma Clinical Trial using chemotherapy

Yonsei University - Recruiting 18 years or older.
- .
chemotherapy

Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Clinical Trial using oxaliplatin; irinotecan hydrochloride; leucovorin calcium; fluorouracil; laboratory biomarker analysis

University of Chicago - Recruiting 18 years or older.
- A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies.
oxaliplatin; irinotecan hydrochloride; leucovorin calcium; fluorouracil; laboratory biomarker analysis

Renal Cell Carcinoma Clinical Trial using MPDL3280A; bevacizumab [Avastin]; sunitinib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA.
MPDL3280A; bevacizumab [Avastin]; sunitinib

Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, or Metastati Clinical Trial using Standard Treatment; AGS-003

Argos Therapeutics - Recruiting 18 years or older.
- An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT).
Standard Treatment; AGS-003

Hepatocellular Carcinoma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects With or Without Chronic Viral Hepatitis.
Nivolumab

Lymphedema, Stage IA Cervical Cancer, Stage IA Endometrial Carcin Clinical Trial using therapeutic lymphadenectomy; therapeutic conventional surgery; therapeutic laparoscopic surgery; study of high risk factors; questionnaire administration; psychosocial assessment and care; quality-of-life assessment

Gynecologic Oncology Group - Recruiting 18 years or older.
- The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients.
therapeutic lymphadenectomy; therapeutic conventional surgery; therapeutic laparoscopic surgery; study of high risk factors; questionnaire administration; psychosocial assessment and care; quality-of-life assessment

Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, C Clinical Trial using live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Phase II Evaluation of ADXS11-001 (NSC 752718, BB-IND#13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix.
live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001; laboratory biomarker analysis

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy.
laboratory biomarker analysis

Actinic Keratosis, or Squamous Cell Carcinoma Clinical Trial using Superficial shave biopsy

Northwestern University - Recruiting 18 years to 89 years.
- Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients.
Superficial shave biopsy

Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Ca Clinical Trial using cisplatin; paclitaxel; carboplatin; brachytherapy

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
cisplatin; paclitaxel; carboplatin; brachytherapy

Endometrial Cancer Clinical Trial using cisplatin; brachytherapy; external beam radiation therapy

Gynecologic Oncology Group - Recruiting N/A or older.
- A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus.
cisplatin; brachytherapy; external beam radiation therapy

Carcinoma, Hepatocellular Clinical Trial using LY2157299; Sorafenib

Eli Lilly and Company - Recruiting 18 years or older.
- Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma.
LY2157299; Sorafenib

Ovarian Carcinoma Clinical Trial using Ovarian Cancer Screening; Prophylactic Salpingectomy with Delayed Oophorectomy; Risk-Reducing Salpingo-Oophorectomy; Questionnaire; Transvaginal Ultrasound; Phone Call

M.D. Anderson Cancer Center - Recruiting 35 years to 46 years.
- Prophylactic Salpingectomy With Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, and Ovarian Cancer Screening Among BRCA Mutation Carriers: A Proof-of-Concept Study.
Ovarian Cancer Screening; Prophylactic Salpingectomy with Delayed Oophorectomy; Risk-Reducing Salpingo-Oophorectomy; Questionnaire; Transvaginal Ultrasound; Phone Call

Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, or Locall Clinical Trial using FOLFIRINOX; Algenpantucel-L Immunotherapy; 5-FU Chemoradiation; Gemcitabine; Capecitabine; Nab-Paclitaxel

NewLink Genetics Corporation - Recruiting 18 years or older.
- A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcuter-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
FOLFIRINOX; Algenpantucel-L Immunotherapy; 5-FU Chemoradiation; Gemcitabine; Capecitabine; Nab-Paclitaxel

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?.
behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, or Me Clinical Trial using Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT.
Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Cancer Metastatic to the Liver, Hepatocellular Carcinoma That is Clinical Trial using PV-10 (10% rose bengal disodium)

Provectus Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.
PV-10 (10% rose bengal disodium)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM Clinical Trial using BYL719+cetuximab; cetuximab

Novartis - Recruiting 18 years or older.
- A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
BYL719+cetuximab; cetuximab

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using elesclomol sodium; paclitaxel

Gynecologic Oncology Group - Recruiting 18 years or older.
- A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
elesclomol sodium; paclitaxel

Metastatic Renal Cell Carcinoma Clinical Trial using RAD001

Novartis - Recruiting 18 years or older.
- An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma.
RAD001

Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, C Clinical Trial using laboratory biomarker analysis; lymphadenectomy

Gynecologic Oncology Group - Recruiting 18 years or older.
- Glycoprotein and Glycan Profiling in Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA > 4 CM, IIB to IVA) Undergoing Pelvic and Para-Aortic (Abdominal) Lymphadenectomy.
laboratory biomarker analysis; lymphadenectomy

Biochemical-recurrent Only Epithelial Ovarian Cancer, Primary Per Clinical Trial using INCB024360; tamoxifen

Incyte Corporation - Recruiting 18 years or older.
- A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy.
INCB024360; tamoxifen

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Clinical Trial using bavituximab; Docetaxel; Placebo (for bavituximab)

Peregrine Pharmaceuticals - Recruiting 18 years or older.
- SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer.
bavituximab; Docetaxel; Placebo (for bavituximab)

Invasive Ductal Carcinoma, or Ductal Carcinoma in Situ Clinical Trial using Intra-operative Radiation Therapy - IORT

Xoft, Inc. - Recruiting 40 years or older.
- A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoftr Axxentr eBxT System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer.
Intra-operative Radiation Therapy - IORT

Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breas Clinical Trial using therapeutic conventional surgery; radiation therapy; quality-of-life assessment

Roswell Park Cancer Institute - Recruiting 50 years or older.
- Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer.
therapeutic conventional surgery; radiation therapy; quality-of-life assessment

Carcinoma, Hepatocellular Clinical Trial using Refametinib (BAY86-9766)

Bayer - Recruiting 18 years or older.
- A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC).
Refametinib (BAY86-9766)

Pseudomyxoma Peritonei, Colorectal Carcinoma, Ovarian Carcinoma, Clinical Trial using CRS-HIPEC

Oslo University Hospital - Recruiting 18 years or older.
- Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies..
CRS-HIPEC

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using yttrium Y 90 glass microspheres; laboratory biomarker analysis

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Humanitarian Device Exemption Treatment Protocol of TheraSpherer For Treatment of Unresectable Hepatocellular Carcinoma.
yttrium Y 90 glass microspheres; laboratory biomarker analysis

Basal Cell Carcinoma Clinical Trial using vismodegib; placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas.
vismodegib; placebo

Squamous Cell Carcinoma, or Head and Neck Cancer Clinical Trial using EGFR Antisense DNA

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- Safety and Efficacy of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
EGFR Antisense DNA

Basal Cell Carcinoma Clinical Trial using vismodegib

Hoffmann-La Roche - Recruiting 18 years or older.
- A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC).
vismodegib

Carcinoma, Renal Cell, or Lymphoma, Mantle-Cell Clinical Trial using Temsirolimus (Non-Interventional Study)

Pfizer - Recruiting 18 years or older.
- INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus.
Temsirolimus (Non-Interventional Study)

Head and Neck Cancer, or Squamous Cell Carcinoma of the Head and Clinical Trial using Cisplatin; Docetaxel; Erlotinib; Placebo; Carboplatin

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel And Cisplatin With Or Without Erlotinib In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of the Head And Neck.
Cisplatin; Docetaxel; Erlotinib; Placebo; Carboplatin

Head and Neck Squamous Cell Carcinoma Clinical Trial using AFATINIB; Placebo of AFATINIB

Centre Leon Berard - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02.
AFATINIB; Placebo of AFATINIB

Hepatocellular Carcinoma Clinical Trial using HepaSphere/QuadraSphere Microspheres; PVA, lipiodol, doxorubicin

Merit Medical Systems, Inc. - Recruiting 18 years or older.
- Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma.
HepaSphere/QuadraSphere Microspheres; PVA, lipiodol, doxorubicin

Renal Cell Carcinoma(RCC) Clinical Trial using Anlotinib hydrochloric capsule

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd - Recruiting 18 years to 75 years.
- A Phase II Study of Anlotinib(AL3818) Hydrochloric Capsule in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy.
Anlotinib hydrochloric capsule

Carcinoma, Squamous Cell of Head and Neck Clinical Trial using Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer (CTRC# 11-36).
Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery

Primary Esophageal Carcinoma Clinical Trial using Bevacizumab

VU University Medical Center - Recruiting 18 years or older.
- Pilot Study to Determine the Effect of Fractionated Radiotherapy on Expression of Pro-angiogenic Factors in Oesophagus Carcinoma.
Bevacizumab

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Adult Primary Hepatocellular Carcinoma, Adult Primary Undifferent Clinical Trial using sorafenib tosylate; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting N/A or older.
- Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC.
sorafenib tosylate; laboratory biomarker analysis

Anlotinib, or RCC Clinical Trial using Anlotinib hydrochloric capsule; Sunitinib maleate

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd - Recruiting 18 years to 75 years.
- A Randomized, Positive-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) Hydrochloric Capsule in Patients With Advanced Renal Cell Carcinoma(RCC).
Anlotinib hydrochloric capsule; Sunitinib maleate

Carcinoma, Hepatocellular Clinical Trial

National Taiwan University Hospital - Recruiting 20 years or older.
- Combination of Dynamic Contrast-enhanced and Diffusion-weighted Imaging and Magnetic Resonance Spectroscopy in 3T MRI to Early Predict Treatment Efficacy in Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma.

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Car Clinical Trial using niraparib; Physician's choice

Tesaro, Inc. - Recruiting 18 years or older.
- A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients.
niraparib; Physician's choice

Head and Neck Squamous Cell Carcinoma Clinical Trial using Paclitaxel; Carboplatin; Cetuximab; Docetaxel; Cisplatin; Fluorouracil; Radiotherapy (RT); Chemotherapy

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Paclitaxel; Carboplatin; Cetuximab; Docetaxel; Cisplatin; Fluorouracil; Radiotherapy (RT); Chemotherapy

Thymoma, Thymic Carcinoma, or Clinical Masaoka Stage II-IVA Clinical Trial using Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma.
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide

Pain, Postoperative, or Hepatocellular Carcinoma Clinical Trial using Pregabalin; Placebo (for Pregabalin)

Eastern Hepatobiliary Surgery Hospital - Recruiting 18 years to 70 years.
- A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 150 mg Will Improve Pain Control in Patients With Hepatocellular Carcinoma Undergoing Partial Hepatectomy.
Pregabalin; Placebo (for Pregabalin)

Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, C Clinical Trial using triapine; cisplatin; external beam radiation therapy; brachytherapy; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study of Intravenous 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP, Triapiner NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and Stage II-IVA Vaginal Cancer.
triapine; cisplatin; external beam radiation therapy; brachytherapy; laboratory biomarker analysis

Metastatic Renal Cell Carcinoma Clinical Trial using Sunitinib

VU University Medical Center - Recruiting 18 years or older.
- Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma.
Sunitinib

Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, o Clinical Trial using dimethane sulfonate (DMS612, NSC 281612)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies.
dimethane sulfonate (DMS612, NSC 281612)

Small Cell Lung Carcinoma, or Malignant Epithelial Neoplasms Clinical Trial using (Belinostat) (PDX101); Cisplatin; Etoposide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin.
(Belinostat) (PDX101); Cisplatin; Etoposide

Adrenocortical Carcinoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 12 years or older.
- Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma.

Multiple Endocrine Neoplasia Type 2A, or Multiple Endocrine Neopl Clinical Trial using ZACTIMA (Vandetanib)

National Institutes of Health Clinical Center (CC) - Recruiting 5 years to 18 years.
- Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma.
ZACTIMA (Vandetanib)

Hemangioblastoma, Hereditary Neoplastic Syndrome, Hippel Lindau D Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders.

Liver Cell Caricinoma, Liver Cancer, or Hepatocellular Carcinoma Clinical Trial using Tremelimumab; Trans-Arterial Cather Chemoembolization; Radiofrequency Ablation (RFA)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of Tremelimumab, A Monoclonal Antibody Against CTLA-4, in Combination With Either Trans-Arterial Catheter Chemoembolization (TACE) or Radiofrequency Ablation (RFA) in Subjects With Hepatocellular Carcinoma (HCC).
Tremelimumab; Trans-Arterial Cather Chemoembolization; Radiofrequency Ablation (RFA)

Renal Cell Carcinoma, Graft-Versus-Host Disease, or Engraftment S Clinical Trial using Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area.

Renal Cell Carcinoma Clinical Trial using Bevacizumab; Ixempra (Ixbepilone [BMS-247550]

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma.
Bevacizumab; Ixempra (Ixbepilone [BMS-247550]

Head and Neck Cancer Clinical Trial using Docetaxel; Cisplatin; Cetuximab; Carboplatin

Stanford University - Recruiting 16 years or older.
- Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With SCCHN.
Docetaxel; Cisplatin; Cetuximab; Carboplatin

Squamous Cell Carcinoma of the Oral Cavity, or Squamous Cell Carc Clinical Trial using GC4419

Galera Therapeutics, Inc. - Recruiting 18 years or older.
- A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck..
GC4419

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Carc Clinical Trial using Tivozanib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Tivozanib

Adrenocortical Carcinoma, or Peritoneal Carcinomatosis Clinical Trial using Surgical resection and debulking; Heated intraperitoneal chemotherapy; Cisplatin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma.
Surgical resection and debulking; Heated intraperitoneal chemotherapy; Cisplatin

Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma Clinical Trial using Behavioral dietary intervention; Therapeutic conventional surgery; Radiation therapy; Counseling intervention; Quality-of-life assessment

Thomas Jefferson University - Recruiting 18 years or older.
- A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients.
Behavioral dietary intervention; Therapeutic conventional surgery; Radiation therapy; Counseling intervention; Quality-of-life assessment

Small Cell Lung Carcinoma Clinical Trial using BAY1000394; Etoposide; Cisplatin; Carboplatin

Bayer - Recruiting 18 years or older.
- Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer.
BAY1000394; Etoposide; Cisplatin; Carboplatin

Hepatocellular Carcinoma Clinical Trial using Sorafenib; Doxorubicin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib.
Sorafenib; Doxorubicin

Advanced Adult Hepatocellular Carcinoma, or Hepatocellular Carcin Clinical Trial using AZD9150

AstraZeneca - Recruiting 18 years or older.
- A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma.
AZD9150

Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial C Clinical Trial using IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 19 years or older.
- A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.
IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

Hepatocellular Carcinoma Clinical Trial using Vitamin B-6; Coenzyme Q10; Vitamin B-6+Coenzyme Q10; Placebo

Taichung Veterans General Hospital - Recruiting 20 years to 80 years.
- .
Vitamin B-6; Coenzyme Q10; Vitamin B-6+Coenzyme Q10; Placebo

Solid Tumors, Lymphoma, or Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib; Gefitinib

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies.
LY2875358; Erlotinib; Gefitinib

Pancreatic Carcinoma Non-resectable Clinical Trial using CyberKnifer Stereotactic Body Radiotherapy(SBRT)Boost

Ottawa Hospital Research Institute - Recruiting 19 years to 80 years.
- Phase I Time-to-Event Continual Reassessment (TITE-CRM) Dose Escalation Trial of CyberKnifer Stereotactic Body Radiotherapy (SBRT) Boost With Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Pancreatic Cancer.
CyberKnifer Stereotactic Body Radiotherapy(SBRT)Boost

Head and Neck Cancer, Oral Cavity Cancer, or Oropharyngeal Cancer Clinical Trial using Valproic Acid

Instituto do Cancer do Estado de Sao Paulo - Recruiting N/A to 65 years.
- Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Valproic Acid

Endometrial Adenocarcinoma, Endometrial Papillary Serous Carcinom Clinical Trial using trametinib; Akt inhibitor GSK2141795; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study With Safety Lead-in to Assess the Antitumor Efficacy of the Mek Inhibitor Trametinib Alone or in Combination With GSK2141795, an Akt Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer.
trametinib; Akt inhibitor GSK2141795; laboratory biomarker analysis

Hepatocellular Carcinoma Clinical Trial using MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

SYZ Cell Therapy Co.. - Recruiting 20 years to 70 years.
- Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens.
MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

Lung Cancer, Small Cell Clinical Trial using GSK2879552

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma.
GSK2879552

Carcinoma, Renal Cell Clinical Trial using Pazopanib

GlaxoSmithKline - Recruiting 18 years or older.
- PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib.
Pazopanib

Renal Cell Carcinoma Clinical Trial using Arterial Spin Labeling Magnetic Resonance Imaging

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma.
Arterial Spin Labeling Magnetic Resonance Imaging

Hepatocellular Carcinoma Clinical Trial using everolimus; everolimus placebo

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitorr) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study.
everolimus; everolimus placebo

Clear Cell Renal Cell Carcinoma, or Stage IV Renal Cell Cancer Clinical Trial using entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma.
entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

Cervical Cancer, Uterine Cancer, Vaginal Cancer, or Carcinoma of Clinical Trial using Image-guided brachytherapy

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO).
Image-guided brachytherapy

Urothelial Carcinoma Clinical Trial using Gemcitabine; Cisplatin; Ipilimumab

Hoosier Oncology Group - Recruiting 18 years or older.
- Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU10-148.
Gemcitabine; Cisplatin; Ipilimumab

Bladder Cancer, or Urothelial Carcinoma Clinical Trial using OGX-427; Docetaxel

Hoosier Oncology Group - Recruiting 18 years or older.
- The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Oncology Group GU12-160.
OGX-427; Docetaxel

Bladder Cancer Clinical Trial using Dovitinib

Hoosier Oncology Group - Recruiting 18 years or older.
- A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Oncology Group GU12-157.
Dovitinib

Thymoma, or Thymus Neoplasms Clinical Trial using Sunitinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy.
Sunitinib

Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyr Clinical Trial using dabrafenib; trametinib; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma.
dabrafenib; trametinib; Correlative Studies

Transitional Cell Carcinoma, Bladder Carcinoma, or Urothelial Car Clinical Trial using Everolimus; Paclitaxel

Hoosier Oncology Group - Recruiting 18 years or older.
- Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU10-147.
Everolimus; Paclitaxel

Colorectal Cancers Clinical Trial using RENCA macrobeads

The Rogosin Institute - Recruiting 18 years or older.
- A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma.
RENCA macrobeads

Breast Cancer, or DCIS Clinical Trial using HER-2 Pulsed Dendritic cell Vaccine

University of Pennsylvania - Recruiting 18 years or older.
- A Randomized Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS.
HER-2 Pulsed Dendritic cell Vaccine

Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, C Clinical Trial using quality-of-life assessment; questionnaire administration; cone biopsy; loop electrosurgical excision procedure

Gynecologic Oncology Group - Recruiting 18 years or older.
- Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/<2CM) Cervical Cancer.
quality-of-life assessment; questionnaire administration; cone biopsy; loop electrosurgical excision procedure

Carcinoma, Squamous Cell of Head and Neck Clinical Trial using VTX-2337; Carboplatin; Cisplatin; 5-fluorouracil; Placebo

VentiRx Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
VTX-2337; Carboplatin; Cisplatin; 5-fluorouracil; Placebo

Confirmed Diagnosis of HCC;, Patients Who Are Scheduled to Underg Clinical Trial using TACE or Systemic Therapy

Chinese University of Hong Kong - Recruiting 18 years or older.
- A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Unresectable Hepatocellular Carcinoma.
TACE or Systemic Therapy

Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Clinical Trial using doxorubicin hydrochloride; cisplatin; paclitaxel; filgrastim; pegfilgrastim

Gynecologic Oncology Group - Recruiting N/A or older.
- A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure.
doxorubicin hydrochloride; cisplatin; paclitaxel; filgrastim; pegfilgrastim

Unresectable Hepatocellular Carcinoma With Portal Vein Thrombosis Clinical Trial using TheraSphere; Sorafenib

BTG International Inc. - Recruiting 18 years or older.
- A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSpherer) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT).
TheraSphere; Sorafenib

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line..

Basal Cell Carcinoma Clinical Trial using vismodegib; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study To Assess The Efficacy And Safety Of Oral Vismodegib For The Treatment Of Basal Cell Carcinoma Preceding Excision By Mohs Micrographic Surgery.
vismodegib; Placebo

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using zoledronic acid; laboratory biomarker analysis; therapeutic conventional surgery

City of Hope Medical Center - Recruiting N/A or older.
- A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer.
zoledronic acid; laboratory biomarker analysis; therapeutic conventional surgery

Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ Clinical Trial using docosahexaenoic acid; placebo; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.
docosahexaenoic acid; placebo; laboratory biomarker analysis

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma.
gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

Carcinoma, Non-Small Cell Lung Clinical Trial using Radiation Therapy and EGFR-TKI target therapy

Tianjin Medical University Cancer Institute and Hospital - Recruiting 18 years to 70 years.
- A Phase II Study on the Safety and Efficacy of Radiation Therapy and Concurrent Erlotinib in Locally Advanced Non-small-cell Lung Cancer.
Radiation Therapy and EGFR-TKI target therapy

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab Alone or in Combination With TRC 105 for Advanced Renal Cell Cancer.
bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

Hepatocellular Carcinoma Clinical Trial using TACE with Hyperthermia Treatment

Chinese University of Hong Kong - Recruiting 18 years to 75 years.
- A Pilot Study on the Feasibility of Combined Chemoembolization and Adjuvant Systemic Hyperthermia for Palliative Treatment of Unresectable Hepatocellular Carcinoma(HCC).
TACE with Hyperthermia Treatment

Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Clinical Trial using cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using tivozanib; pharmacological study; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma.
tivozanib; pharmacological study; laboratory biomarker analysis

Bladder Cancer Clinical Trial using Everolimus and Intravesical Gemcitabine

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder.
Everolimus and Intravesical Gemcitabine

Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, or Gastro Clinical Trial using Temsirolimus; Sunitinib; Axitinib

Pfizer - Recruiting 18 years or older.
- STAR-TOR - Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Toriselr), Sunitinib (Sutentr), and Axitnib (Inlytar) for the Treatment of Subjects With Advanced Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST).
Temsirolimus; Sunitinib; Axitinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using PF-02341066

Pfizer - Recruiting 18 years or older.
- Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene.
PF-02341066

Renal Cell Carcinoma Clinical Trial using Temsirolimus

Pfizer - Recruiting N/A or older.
- Torisel Special Investigation (Regulatory Post Marketing Commitment Plan).
Temsirolimus

NSCLC (Non-small Cell Lung Cancer) Clinical Trial using Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Pfizer - Recruiting 18 years to 70 years.
- Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Renal Cell Carcinoma Clinical Trial using Temsirolimus

Pfizer - Recruiting N/A or older.
- Torisel Drug Use Investigation (Regulatory Post Marketing Commitment Plan).
Temsirolimus

Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, or Carcinoma, Hep Clinical Trial using TRC 105; Sorafenib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC).
TRC 105; Sorafenib

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Nasopharyngeal Carcinoma, or Radiation Therapy Complication Clinical Trial using Atorvastatin; Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University - Recruiting 40 years to 65 years.
- Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis: A Multicenter, Double-blind, Placebo-Controlled, Randomized Trial.
Atorvastatin; Placebo

Unresectable Hepatocellular Carcinoma Clinical Trial using TheraSphere

BTG International Inc. - Recruiting 18 years or older.
- A Phase III Clinical Trial of Intra-arterial TheraSpherer in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC).
TheraSphere

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma).
Sorafenib (Nexavar, BAY43-9006)

Thymoma and Thymic Carcinoma Clinical Trial using Everolimus

Istituto Clinico Humanitas - Recruiting 18 years or older.
- Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy.
Everolimus

Nasopharyngeal Carcinoma Clinical Trial using OPB-51602

National University Hospital, Singapore - Recruiting 21 years or older.
- The Signal Transducer and Activator of Transcription (STAT)3 Pathway and the Development of STAT3 Phosphorylation Inhibitors as Cancer Therapy: Lead-In Phase I Dose-Escalating, Open-Label, Non-Randomised Study of A Weekly Regimen OPB-51602 in Advanced Refractory Solid Tumours With Enrichment Cohorts of Nasopharyngeal Carcinoma Followed By A Biomarker Study Evaluating OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy.
OPB-51602

Carcinoma, Hepatocellular Clinical Trial using Regorafenib (BAY73-4506); Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib.
Regorafenib (BAY73-4506); Placebo

Renal Cell Carcinoma Clinical Trial using questionnaire

Mayo Clinic - Recruiting 18 years or older.
- Renal Mass Registry.
questionnaire

Effects of Chemotherapy, or Stage IVC Nasopharyngeal Carcinoma Clinical Trial using Recombinant Human Endostatin plus gemcitabine and cisplatin; Gemcitabine and cisplatin

Zhejiang Cancer Hospital - Recruiting 18 years to 65 years.
- A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage ? Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma.
Recombinant Human Endostatin plus gemcitabine and cisplatin; Gemcitabine and cisplatin

Non-Small Cell Lung Carcinoma Clinical Trial using CV9202

CureVac GmbH - Recruiting 18 years or older.
- An Exploratory, Open-label Phase Ib Study of RNActiver-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor.
CV9202

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer..

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region..

Stage I Breast Carcinoma, or Stage II Breast Carcinoma Clinical Trial using intra-operative MRI

Dana-Farber Cancer Institute - Recruiting 18 years to 75 years.
- A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO).
intra-operative MRI

Melanoma, Breast Neoplasms, Lobular Carcinoma, Triple-negative Br Clinical Trial using LGK974

Novartis - Recruiting 18 years or older.
- A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands.
LGK974

Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancre Clinical Trial using temozolomide; capecitabine; laboratory biomarker analysis

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors.
temozolomide; capecitabine; laboratory biomarker analysis

Metastatic Hepatocellular Carcinoma, or Advanced Liver Cancer Clinical Trial using Ascorbic Acid + Sorafenib; Sorafenib alone

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma.
Ascorbic Acid + Sorafenib; Sorafenib alone

Recurrent, or Head and Neck Cancer Clinical Trial using SBRT; Cetuximab; Docetaxel

University of Pittsburgh - Recruiting 18 years or older.
- Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN).
SBRT; Cetuximab; Docetaxel

Transitional Cell Carcinoma of Bladder Clinical Trial using BC-819/PEI; BCG Vaccine

BioCancell Ltd. - Recruiting 18 years or older.
- Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma.
BC-819/PEI; BCG Vaccine

Basal Cell Carcinoma Clinical Trial using Low-Risk BCC Excisional Margins

Thomas Jefferson University - Recruiting N/A or older.
- Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Facial Basl Cell Carcinomas.
Low-Risk BCC Excisional Margins

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using afatinib; placebo; laboratory biomarker analysis

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence.
afatinib; placebo; laboratory biomarker analysis

Nasopharyngeal Carcinoma Clinical Trial using Docetaxel; Carboplatin; Dexamethasone; EBV-specific cytotoxic T lymphocytes

Baylor College of Medicine - Recruiting 10 years or older.
- Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients With Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma(CADEN).
Docetaxel; Carboplatin; Dexamethasone; EBV-specific cytotoxic T lymphocytes

Merkel Cell Carcinoma Clinical Trial using Arm A: F16IL2 in combination with paclitaxel; Arm B: Paclitaxel

Philogen S.p.A. - Recruiting 18 years to 75 years.
- Phase II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Metastatic Merkel Cell Carcinoma.
Arm A: F16IL2 in combination with paclitaxel; Arm B: Paclitaxel

Eye Cancer Clinical Trial using Lymphatic Mapping; SLN Mapping/Biopsy

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Sentinel Lymph Node Localization and Biopsy for Sebaceous Gland Carcinoma of the Eyelid.
Lymphatic Mapping; SLN Mapping/Biopsy

Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, S Clinical Trial using H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

Squamous Cell Carcinoma of the Oral Cavity, or Squamous Cell Carc Clinical Trial using LI plus CIZ; Standard of Care (SOC); LI + SOC

CEL-SCI Corporation - Recruiting 18 years or older.
- Phase III Study of LI [Multikiner] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only.
LI plus CIZ; Standard of Care (SOC); LI + SOC

Head and Neck Squamous Cell Carcinoma Clinical Trial using IMRT; PET/CT; Docetaxel; Fluorouracil; Cisplatin

Lithuanian University of Health Sciences - Recruiting 18 years to 75 years.
- Assessing Tumor Response and IMRT Treatment Planning After Induction Chemotherapy Based on FDG-PET/CT for Locally Advanced Head and Neck Squamous Cell Carcinoma..
IMRT; PET/CT; Docetaxel; Fluorouracil; Cisplatin

Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Clinical Trial using RAD001

Novartis - Recruiting 18 years or older.
- A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer.
RAD001

Head and Neck Cancer Clinical Trial using 6 weeks of Radiotherapy; 5 weeks of Radiotherapy

University of California, Davis - Recruiting 18 years or older.
- Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV).
6 weeks of Radiotherapy; 5 weeks of Radiotherapy

Carcinoma, Squamous Cell, Head and Neck Neoplasms, or Oropharynge Clinical Trial using Assessment of Oral HPV Infection

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Monitoring of Oral HPV Infection in HPV-positive Oropharyngeal Squamous Cell Carcinoma During and After Chemoradiotherapy (CRT).
Assessment of Oral HPV Infection

Metastatic Transitional Cell Carcinoma of the Urothelium Clinical Trial using Buparlisib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Study of Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium.
Buparlisib

Small Cell Lung Carcinoma Clinical Trial using Ipilimumab; Placebo matching Ipilimumab; Etoposide; Cisplatin; Carboplatin

Bristol-Myers Squibb - Recruiting 18 years or older.
- Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC).
Ipilimumab; Placebo matching Ipilimumab; Etoposide; Cisplatin; Carboplatin

Colorectal Cancer Clinical Trial using RAD011; FOLFOX; Bevacizumab

University of Utah - Recruiting N/A or older.
- A Phase I/II Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma.
RAD011; FOLFOX; Bevacizumab

Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, or Irin Clinical Trial using Carfilzomib; Irinotecan

Cancer Research and Biostatistics Clinical Trials Consortium - Recruiting 18 years or older.
- Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy.
Carfilzomib; Irinotecan

Carcinoma, Renal Cell Clinical Trial using Pazopanib; MK-3475

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma.
Pazopanib; MK-3475

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

University of Washington - Recruiting 18 years or older.
- Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).
TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

Head and Neck Cancer Clinical Trial using Everolimus escalating dose; Everolimus or Placebo

University of Chicago - Recruiting 18 years to 89 years.
- Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Everolimus escalating dose; Everolimus or Placebo

Carcinoma, Hepatocellular Clinical Trial using Refametinib (BAY86-9766); Sorafenib (BAY43-9006)

Bayer - Recruiting 18 years or older.
- A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC).
Refametinib (BAY86-9766); Sorafenib (BAY43-9006)

Nasopharyngeal Carcinoma Clinical Trial using nitrate supplementation; Placebo

Capital Medical University - Recruiting 20 years to 60 years.
- Study of Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients Receiving Concurrent Chemo-radiotherapy.
nitrate supplementation; Placebo

Carcinoma, Non-small Cell Lung Clinical Trial using Dasatinib

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation.
Dasatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib; erlotinib

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy.
afatinib; erlotinib

Renal Cell Carcinoma Clinical Trial using Pazopanib

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- A Phase II Study of Pazopanib in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC) Who Have Failed Prior Sunitinib Therapy.
Pazopanib

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), o Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer.

Renal Cell Carcinoma Clinical Trial using Everolimus; GDC-0980

Genentech - Recruiting 18 years or older.
- A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy.
Everolimus; GDC-0980

Differentiated Thyroid Cancer (DTC), or Poorly Differentiated Thy Clinical Trial using Cabozantinib

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting.
Cabozantinib

Liver Cancer Clinical Trial using onartuzumab; sorafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB GIVEN AS A SINGLE AGENT AND IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
onartuzumab; sorafenib

Hepatocellular Carcinoma Clinical Trial using No Intervention

Bayer - Recruiting 18 years or older.
- Profile of the Hepatocellular Carcinoma Patients in Turkey.
No Intervention

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- THE SURVIVAL OF NON SMALL CELL LUNG CARCINOMA EGFR NON-MUTATED (WILD TYPE) PATIENTS TREATED WITH ERLOTINIB (TARCEVA) AFTER THE FAILURE OF AT LEAST ONE CHEMOTHERAPY REGIMEN..

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma.
Sorafenib (Nexavar, BAY43-9006)

Renal Cell Carcinoma Clinical Trial using No intervention

Bayer - Recruiting 18 years or older.
- Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma.
No intervention

Prostate Cancer, Salivary Gland Cancer, Endometrial Cancer, Squam Clinical Trial using OPB-111001

Otsuka Novel Products GmbH - Recruiting 18 years or older.
- A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment.
OPB-111001

Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Clinical Trial using pazopanib hydrochloride; placebo; quality-of-life assessment; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors.
pazopanib hydrochloride; placebo; quality-of-life assessment; laboratory biomarker analysis

Hepatocellular Carcinoma, Hepatocellular Cancer, or Carcinoma, He Clinical Trial using TRC105

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 80 years.
- A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib.
TRC105

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib.
LY2875358; Erlotinib

Carcinoma, Hepatocellular, or Carcinoma, Renal Cell Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- Regulatory Post Marketing Surveillance Study on Nexavarr.
Sorafenib (Nexavar, BAY43-9006)

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib.
LY2875358; Erlotinib

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent.
Sorafenib (Nexavar, BAY43-9006)

Hepatocellular Carcinoma Clinical Trial using SGI-110

Astex Pharmaceuticals - Recruiting 18 years or older.
- A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib.
SGI-110

Epithelial Ovarian Cancer Clinical Trial using CAELYX; Topotecan HCl

Xian-Janssen Pharmaceutical Ltd. - Recruiting 18 years or older.
- A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYXr Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy.
CAELYX; Topotecan HCl

Advanced or Metastatic (Medically or Surgically Unresectable) Cle Clinical Trial using Nivolumab; Everolimus

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy.
Nivolumab; Everolimus

Adrenocortical Carcinoma Clinical Trial using ATR-101

Atterocor, Inc. - Recruiting 18 years or older.
- Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma.
ATR-101

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Carcinoma, Renal Cell Clinical Trial using Sorafenib( Nexavar, BAY43-9006)

Bayer - Recruiting 65 years or older.
- Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib.
Sorafenib( Nexavar, BAY43-9006)

Nasopharynx Cancer Clinical Trial using Data Consolidation and Analysis

University of Florida - Recruiting 18 years or older.
- A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx.
Data Consolidation and Analysis

Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage Clinical Trial using pazopanib hydrochloride; therapeutic conventional surgery

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Pazopanib to Enable Partial Nephrectomy.
pazopanib hydrochloride; therapeutic conventional surgery

Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, or Ca Clinical Trial using Rapamycin; Biopsy; Dynamic CT Perfusion; Positron Emission Tomography; Measurement Serum Cytokines

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 80 years.
- A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer.
Rapamycin; Biopsy; Dynamic CT Perfusion; Positron Emission Tomography; Measurement Serum Cytokines

Hepatocellular Carcinoma Clinical Trial using TACE+EBRT; Sorafenib

Asan Medical Center - Recruiting 20 years or older.
- Randomized Phase II Trial Comparing Transarterial Chemoembolization Plus External Beam Radiotherapy Versus Sorafenib in Patients With Hepatocellular Carcinoma With Major Vascular Invasion.
TACE+EBRT; Sorafenib

Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Nec Clinical Trial using ADXS11-001 (ADXS-HPV)

Mount Sinai School of Medicine - Recruiting 18 years or older.
- Window of Opportunity Trial of Neoadjuvant ADXS 11-001 Vaccination Prior to Robot -Assisted Resection of HPV-Positive Oropharyngeal Squamous Cell Carcinoma.
ADXS11-001 (ADXS-HPV)

Skin Cancer of the Head and Neck Clinical Trial

University of Florida - Recruiting 18 years or older.
- A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Skin of the Head and Neck With Perineural Invasion.

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using Cabazitaxel; Methotrexate

Cliniques universitaires Saint-Luc- Universit‚ Catholique de Louvain - Recruiting 18 years or older.
- Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Therapy..
Cabazitaxel; Methotrexate

Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Ad Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 18 years or older.
- Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies.
ADI-PEG 20

Carcinoma Clinical Trial

Washington University School of Medicine - Recruiting N/A or older.
- Registry for Proton Beam Radiation Therapy.

Ovarian Epithelial Cancer, Carcinoma in Situ, or Ovarian Cancer Clinical Trial using Lavage of the Cavum uteri and proximal Fallopian tubes

Medical University of Vienna - Recruiting 18 years to 80 years.
- Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma.
Lavage of the Cavum uteri and proximal Fallopian tubes

Recurrent Squamous Cell Carcinoma of the Nasopharynx, or Stage IV Clinical Trial using Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.
Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Clinical Trial using ipilimumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies.
ipilimumab; laboratory biomarker analysis

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers.
6,8-bis(benzylthio)octanoic acid

Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Ce Clinical Trial using Docetaxel; Cisplatin; 5-fluorouracil; Cetuximab Induction; Cetuximab Radioimmunotherapy; Boost irradiation

Arbeitsgemeinschaft medikamentoese Tumortherapie - Recruiting 18 years to 75 years.
- Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck.
Docetaxel; Cisplatin; 5-fluorouracil; Cetuximab Induction; Cetuximab Radioimmunotherapy; Boost irradiation

Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Ca Clinical Trial using Cisplatin; Gemcitabine; ALT-801

Altor Bioscience Corporation - Recruiting 18 years or older.
- A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.
Cisplatin; Gemcitabine; ALT-801

Advanced Gastric Cancer, or Esophagogastric Junction Cancer Clinical Trial using Paclitaxel; RAD001

Krankenhaus Nordwest - Recruiting 18 years or older.
- A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.
Paclitaxel; RAD001

Squamous-cell Cervical Carcinoma Stage IB2 to IIB Without Spread Clinical Trial using 18F-FDG-PET

Hospices Civils de Lyon - Recruiting 18 years or older.
- Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy.
18F-FDG-PET

Gastric Adenocarcinoma Clinical Trial using HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin; Curative gastrectomy

Hospices Civils de Lyon - Recruiting 18 years to 75 years.
- GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A National Randomized and Multicentric Phase III Study..
HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin; Curative gastrectomy

Carcinoma, Hepatocellular Clinical Trial using PF-03446962; Best Supportive Care; Best supportive care

Pfizer - Recruiting 18 years or older.
- A Phase 2, Randomized, Open Label Study To Evaluate The Efficacy, Safety, Pharmacodynamics, Pharmacokinetics Of The Anti-ALK-1 MAB PF-03446962 In Combination With Best Supportive Care VS. Best Supportive Care Alone In Adult Patients With Advanced Hepatocellular Carcinoma.
PF-03446962; Best Supportive Care; Best supportive care

Medullary Thyroid Carcer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Longitudinal Assessment and Natural History Study of Children and Young Adults With Medullary Thyroid Carcinoma.

Merkel Cell Carcinoma Clinical Trial using GLA-SE

Immune Design - Recruiting 18 years to 80 years.
- A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma.
GLA-SE

Renal Cell Carcinoma Clinical Trial using BKM-120 Bevacizumab

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies.
BKM-120 Bevacizumab

Colorectal Neoplasms, Colorectal Carcinoma, or Colorectal Tumors Clinical Trial using ISIS 183750; Irinotecan

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer.
ISIS 183750; Irinotecan

Carcinoma Hepatocellular Clinical Trial using RT and hyperthermia after TACE

Samsung Medical Center - Recruiting 20 years or older.
- Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis: Prospective Phase II Trial.
RT and hyperthermia after TACE

Liver Cancer Clinical Trial using doxorubicin-eluting beads; everolimus; placebo

Swiss Group for Clinical Cancer Research - Recruiting 18 years or older.
- A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolization (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma.
doxorubicin-eluting beads; everolimus; placebo

Endometrial Cancer Clinical Trial using Metformin; Letrozole; Everolimus

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma.
Metformin; Letrozole; Everolimus

Colorectal Carcinoma, or CRC Clinical Trial using JX-594; Irinotecan

Jennerex Biotherapeutics - Recruiting 18 years or older.
- A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma..
JX-594; Irinotecan

Localized Non-Resectable Adult Hepatocellular Carcinoma Clinical Trial using Stereotactic body radiotherapy

Samsung Medical Center - Recruiting 20 years or older.
- Effectiveness and Safety of the Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prospective Phase II Trial.
Stereotactic body radiotherapy

Hepatocellular Carcinoma Clinical Trial

Peking Union Medical College Hospital - Recruiting 18 years to 80 years.
- Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma..

Carcinoma, Hepatocellular Clinical Trial using Stereotactic Body Radiation

Indiana University - Recruiting 18 years or older.
- Multi-institution Phase I/II Dose Escalation Study of Hypofractionated Stereotactic Body Radiation Therapy for Primary Hepatocellular Carcinoma.
Stereotactic Body Radiation

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck.
cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Carcinoma, Non-Small-Cell Lung, or Neoplasm Metastasis Clinical Trial using 34 Gy in a single fraction; 54Gy 18Gy/fr. x 3 fractions; 50Gy (12 x 5 fr.s); 60Gy (7.5Gy x 8fr.)

Institut Catal… d'Oncologia - Recruiting 18 years or older.
- Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases.
34 Gy in a single fraction; 54Gy 18Gy/fr. x 3 fractions; 50Gy (12 x 5 fr.s); 60Gy (7.5Gy x 8fr.)

Renal Cell Carcinoma Clinical Trial using CyberKnife. SBRT

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma.
CyberKnife. SBRT

Kidney Cancer Clinical Trial using aldesleukin; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study.
aldesleukin; bevacizumab

Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamo Clinical Trial using Paclitaxel; Buparlisib; Buparlisib Placebo

Novartis - Recruiting 18 years or older.
- Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Paclitaxel; Buparlisib; Buparlisib Placebo

Non-melanomatous Skin Cancer Clinical Trial using aminolevulinic acid hydrochloride

National Cancer Institute (NCI) - Recruiting 30 years or older.
- Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma.
aminolevulinic acid hydrochloride

Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Lo Clinical Trial using educational intervention; counseling intervention; psychosocial support for caregiver; questionnaire administration; laboratory biomarker analysis

University of Washington - Recruiting N/A or older.
- Psychoeducation for Spouses/Partners of Women With Breast Cancer.
educational intervention; counseling intervention; psychosocial support for caregiver; questionnaire administration; laboratory biomarker analysis

Kidney Cancer Clinical Trial using sunitinib malate; gene expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma.
sunitinib malate; gene expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

Kidney Cancer Clinical Trial using motexafin gadolinium; sunitinib malate; comparative genomic hybridization; gene expression analysis; mutation analysis; polymorphism analysis; immunohistochemistry staining method; iodine I-124 girentuximab; laboratory biomarker analysis; pharmacological study; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Histopathologic and Imaging Study of Renal Cell Carcinoma Vasculature in the Setting of Sunitinib Therapy Prior to Cytoreductive Nephrectomy.
motexafin gadolinium; sunitinib malate; comparative genomic hybridization; gene expression analysis; mutation analysis; polymorphism analysis; immunohistochemistry staining method; iodine I-124 girentuximab; laboratory biomarker analysis; pharmacological study; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

Liver Cancer Clinical Trial using ARQ197; Placebo

Kyowa Hakko Kirin Company, Limited - Recruiting 20 years or older.
- A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy.
ARQ197; Placebo

Colorectal Cancer, Dysgeusia, or Oral Complications of Chemothera Clinical Trial using questionnaire administration; quality-of-life assessment; laboratory biomarker analysis; bovine lactoferrin

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study of Bovine Lactoferrin in Patients With Colorectal Carcinoma Receiving Oxaliplatin-Based Chemotherapy and Self-Reported Taste Disturbances.
questionnaire administration; quality-of-life assessment; laboratory biomarker analysis; bovine lactoferrin

Advanced Hepatocellular Carcinoma, HCC, or Liver Cancer Clinical Trial using PD-0332991

Thomas Jefferson University - Recruiting 18 years or older.
- A Phase II Study of PD-0332991 in Adult Patients With Advanced Hepatocellular Carcinoma.
PD-0332991

Carcinoma, Non-Small-Cell Lung Clinical Trial using BIBW 2992; Sirolimus (rapamycin)

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib.
BIBW 2992; Sirolimus (rapamycin)

Renal Cell Carcinoma Clinical Trial using Axitinib

PrECOG, LLC. - Recruiting 18 years or older.
- NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC).
Axitinib

Oral Mucositis Clinical Trial using SGX942; Placebo

Soligenix - Recruiting 18 years or older.
- A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck.
SGX942; Placebo

Hepatocellular Carcinoma, Clinical Trial using TACE; TACE+ RTC

Nantes University Hospital - Recruiting 18 years or older.
- Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.
TACE; TACE+ RTC

Hepatocellular Carcinoma Clinical Trial using AG-013736

National Taiwan University Hospital - Recruiting 18 years or older.
- Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma.
AG-013736

Liver Cancer Clinical Trial using Lenalidomide

National Taiwan University Hospital - Recruiting 20 years or older.
- Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial.
Lenalidomide

Metastatic Melanoma and Merkel Cell Carcinoma Clinical Trial using Pasireotide sub-cutaneous formulation

Novartis - Recruiting 18 years or older.
- A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c. in Patients With Metastatic Melanoma or Metastatic Merkel Cell Carcinoma.
Pasireotide sub-cutaneous formulation

Pre- and Postoperative Analgesia, Spinal Anesthesia, or Renal Cel Clinical Trial using klonidin; epidural anesthesia

Ume† University - Recruiting 18 years or older.
- Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma.
klonidin; epidural anesthesia

Solid Tumors, or Non-small Cell Lung Carcinoma Clinical Trial using DS-2248

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors.
DS-2248

Kidney Cancer Clinical Trial using Pazopanib; Temsirolimus; Quality of Life Assessment; Benadryl

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.
Pazopanib; Temsirolimus; Quality of Life Assessment; Benadryl

Recurrent Neuroendocrine Carcinoma of the Skin, or Stage IV Neuro Clinical Trial using radiation therapy; recombinant interferon beta; MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma.
radiation therapy; recombinant interferon beta; MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine; aldesleukin; laboratory biomarker analysis

Unresectable Non-metastatic Hepatocellular Carcinoma, or Child A/ Clinical Trial using Zavedosr; Blood samples

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- LIDA-B: Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedosr): Phase I Study.
Zavedosr; Blood samples

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients.
Sorafenib (Nexavar, BAY43-9006)

Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Perito Clinical Trial using Narrow Band Imaging (NBI)

Memorial Sloan-Kettering Cancer Center - Recruiting 19 years or older.
- Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive.
Narrow Band Imaging (NBI)

Advanced Adult Hepatocellular Carcinoma Clinical Trial using Best Supportive Care; sorafenib

National Cancer Institute, Naples - Recruiting 18 years or older.
- Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial.
Best Supportive Care; sorafenib

Renal Cancer Clinical Trial using 124IcG250

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma.
124IcG250

Squamous Cell Carcinoma of the Oropharynx Clinical Trial using questionnaire and semi-structured interviews

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life.
questionnaire and semi-structured interviews

Non-small Cell Lung Carcinoma Clinical Trial using None: Questionnaire Study

University Health Network, Toronto - Recruiting 18 years or older.
- Prospective Observational Study Of Patients With Asymptomatic Centrally Located Advanced NSCLC Who Are Not Suitable For Curative Treatment.
None: Questionnaire Study

Head and Neck Squamous Cell Carcinoma Clinical Trial using Standard RT; Hypofractionated RT

Groupe Oncologie Radiotherapie Tete et Cou - Recruiting 70 years or older.
- Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma.
Standard RT; Hypofractionated RT

Breast Cancer Clinical Trial using Hypofractionated Whole Breast Irradiation; Conventionally Fractionated Whole Breast Irradiation

M.D. Anderson Cancer Center - Recruiting 40 years or older.
- Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer.
Hypofractionated Whole Breast Irradiation; Conventionally Fractionated Whole Breast Irradiation

Oral Cancer, Oropharynx Cancer, or Hypopharynx Cancer Clinical Trial using IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Groupe Oncologie Radiotherapie Tete et Cou - Recruiting 18 years or older.
- Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma.
IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Liver Cancer Clinical Trial using Sorafenib; Yttrium-90 Microspheres; Follow-Up Phone Calls

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C.
Sorafenib; Yttrium-90 Microspheres; Follow-Up Phone Calls

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

Localized Squamous Cell Carcinoma of the Esophagus Clinical Trial using ND-420; Surgery; Cisplatin; fluorouracil

Nang Kuang Pharmaceutical Co., Ltd. - Recruiting 20 years or older.
- A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus.
ND-420; Surgery; Cisplatin; fluorouracil

Kidney Cancer Clinical Trial using Bevacizumab; Temsirolimus

Hellenic Cooperative Oncology Group - Recruiting 18 years or older.
- Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer.
Bevacizumab; Temsirolimus

NSCLC Clinical Trial using Icotinib of routine dose; Icotinib of high dose

Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years.
- An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease.
Icotinib of routine dose; Icotinib of high dose

Nasopharyngeal Cancer Clinical Trial using Adjuvant chemotherapy (gemcitabine and cisplatin)

Chinese University of Hong Kong - Recruiting 18 years or older.
- A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin.
Adjuvant chemotherapy (gemcitabine and cisplatin)

Squamous Cell Carcinoma of the Head and Neck Clinical Trial using docetaxel - cisplatin - 5-fluorouracil; radiotherapy; cetuximab; cisplatin

Gruppo Oncologico del Nord-Ovest - Recruiting 18 years or older.
- Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin.
docetaxel - cisplatin - 5-fluorouracil; radiotherapy; cetuximab; cisplatin

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Oxaliplatin Utilized in Combination Therapy for Adjuvant Treatment of Colon Carcinoma of Stage III After Complete Removal of the Primary Tumor and for Treatment of Metastasizing Colorectal Carcinoma..

Oropharyngeal Squamous Cell Carcinoma, or Supraglottic Squamous C Clinical Trial using Transoral robotic surgery

University of Virginia - Recruiting 18 years or older.
- A Single Arm Study of Efficacy and Functional Quality of Life in Patients Treated With Transoral Robotic Surgery for Oropharyngeal and Supraglottic Squamous Cell Carcinoma.
Transoral robotic surgery

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using ziv-aflibercept; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study to Determine the Effect of 2 Different Doses AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma.
ziv-aflibercept; laboratory biomarker analysis

Hepatocellular Carcinoma Clinical Trial using Sirolimus; m-TOR inhibitor free

Seoul National University Hospital - Recruiting 18 years to 80 years.
- A Randomized Phase ?, Trial With Sirolimus-containing Versus mTOR-inhibitor Free Immunosuppression in Patients Undergoing Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria.
Sirolimus; m-TOR inhibitor free

Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Pre Clinical Trial using sorafenib tosylate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 30 years.
- A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma.
sorafenib tosylate; pharmacological study; laboratory biomarker analysis

Distal Urethral Cancer, Metastatic Transitional Cell Cancer of th Clinical Trial using gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma.
gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystade Clinical Trial using paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I STUDY OF INTRAVENOUS CARBOPLATIN/PACLITAXEL OR INTRAVENOUS AND INTRAPERITONEAL PACLITAXEL/CISPLATIN IN COMBINATION WITH CONTINUOUS OR INTERMITTENT/ CTEP-SUPPLIED AGENT ABT-888 (NSC #737664) AND CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

Hepatocellular Carcinoma Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- Sorafenib Treatment Modalities for HEpatoceLLular Carcinoma Patients in ItAly.
Sorafenib (Nexavar, BAY43-9006)

Hepatocellular Carcinoma Clinical Trial using Liver resection

Seoul National University Hospital - Recruiting 20 years to 80 years.
- Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for Patients With Hepatocellular Carcinoma.
Liver resection

Hepatocellular Carcinoma Clinical Trial using Drug-Eluting Beads (DEB) with Doxorubicin; Lipiodol Ethanol Mixture (LEM)

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma.
Drug-Eluting Beads (DEB) with Doxorubicin; Lipiodol Ethanol Mixture (LEM)

Hepatocellular Carcinoma Clinical Trial using transarterial radioembolization (TARE); transarterial chemoembolization (TACE)

Seoul National University Hospital - Recruiting 20 years to 80 years.
- A Randomized, Multi-center, Open Label, Phase 3 Trial Comparing Conventional TACE and Transarterial Radioembolization in Patients With Unilobar Advanced Hepatocellular Carcinoma.
transarterial radioembolization (TARE); transarterial chemoembolization (TACE)

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase Ib Trial of Concurrent Cetuximab (ERBITUXr) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOYr) in Locally Advanced Head and Neck Cancer.
cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis

Anal Cancer Clinical Trial using Tempol; 5-Fluorouracil; Mitomycin-C; Radiation Therapy

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal.
Tempol; 5-Fluorouracil; Mitomycin-C; Radiation Therapy

Squamous Cell Carcinoma of the Vulva, Stage IIIA Vulvar Cancer, S Clinical Trial using intensity-modulated radiation therapy; gemcitabine hydrochloride; cisplatin; therapeutic conventional surgery

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva.
intensity-modulated radiation therapy; gemcitabine hydrochloride; cisplatin; therapeutic conventional surgery

Liver Cancer Clinical Trial using bevacizumab; erlotinib hydrochloride; sorafenib tosylate

Medical University of South Carolina - Recruiting 18 years or older.
- A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC).
bevacizumab; erlotinib hydrochloride; sorafenib tosylate

Hepatocellular Carcinoma, or Liver Cirrhosis Clinical Trial using Sirsphere trans-arterial radioembolization

Jules Bordet Institute - Recruiting 18 years or older.
- Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver.
Sirsphere trans-arterial radioembolization

Hyperplasia, or Endometrial Cancer Clinical Trial using Levonorgestrel IUD

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma.
Levonorgestrel IUD

Breast Cancer Clinical Trial using Dasatinib and Paclitaxel

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 90 years.
- A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma.
Dasatinib and Paclitaxel